Core Viewpoint - Meihui Biotechnology (Shanghai) Co., Ltd. has been fined 30,000 yuan for false advertising of its "Taikong 30" product during a live-streaming event, as determined by the Shanghai Chongming District Market Supervision Administration [1][5]. Group 1: Company Overview - Meihui Biotechnology is the exclusive e-commerce distributor for the "Junxiaobao" series of products from Shanghai Junxiaobao Health Technology Co., Ltd. [3] - The company is part of the Shanghai Chenguan Health Technology Group, which was founded by Tu Zuitao in 2002 and has since expanded into the probiotics market with the launch of Junxiaobao in 2021 [11]. Group 2: Product and Marketing Strategy - The "Taikong 30" product was marketed as a powerful guardian for women's health, claiming to improve private area conditions within 10 days and alleviate various gynecological issues [4][5]. - Junxiaobao's marketing strategy heavily relies on celebrity endorsements and collaborations with top live-streaming hosts, achieving significant sales figures during promotional events, such as over 50.6 million yuan in GMV from a collaboration with the Guo Yue couple [15]. Group 3: Regulatory Action and Implications - The Shanghai market regulator found that the "Taikong 30" product is merely a regular food item without any therapeutic claims, leading to a violation of the Anti-Unfair Competition Law [5]. - The incident serves as a warning to the industry about the risks of relying solely on traffic-driven marketing without adhering to product integrity and compliance [15].